Tri-Service General Hospital
Taipei, Taiwan
Location status: Recruiting
Location contact
Yi-Chih Hsu, M.D.
CONTACT
NCT Number: NCT06509087
Transarterial microembolization (TAME) is a novel treatment option for chronic musculoskeletal pain, especially suitable for patients who have not responded to conservative treatment or are unsuitable for surgical procedures. This minimally invasive technique primarily targets abnormal neovascularization for embolization, relying heavily on precise information provided by various imaging techniques to ensure the effectiveness and safety of the treatment. This study aims to explore the application of integrating preoperative magnetic resonance imaging (MRI) evidence of patient pain and intraoperative high-resolution synchronous imaging information from fused computed tomography (CT) and angiography systems. This integration is intended to enhance preoperative planning, intraoperative guidance, and final treatment outcome assessment, focusing on its crucial contribution to treatment success. It is hoped that this approach will provide pain intervention physicians with reliable diagnostic tools and safe treatment methods, thereby improving treatment outcomes for patients with chronic musculoskeletal pain.
Interested in participating?
Request Info20 year–80 year
All sexes
Observational
Taipei, Taiwan
Location status: Recruiting
Yi-Chih Hsu, M.D.
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
TAME primarily targets abnormal neovascularization for embolization in chronic shoulder or knee joint pain.
Time frame: day 0, day 1, week 1, month 1, month 3, and month 6.
Pain relief is measured according to the Visual Analog Scale (VAS) immediately prior to (baseline) and after the TAME procedure (day 0) as well as day 1, week 1, month 1, month 3, and month 6.
Time frame: day 0, day 1, week 1, month 1, month 3, and month 6.
Functional improvement is measured according to Shoulder Pain and Disability Index (SPADI) for patients with chronic shoulder pain immediately prior (baseline) to and after the TAME procedure (day 0) as well as day 1, week 1, month 1, month 3, and month 6.
Time frame: day 0, day 1, week 1, month 1, month 3, and month 6.
Functional improvement is measured according to the Western Ontario and McMaster Universities Arthritis Index (WOMAC) for patients with chronic knee pain immediately prior (baseline) to and after the TAME procedure (day 0) as well as day 1, week 1, month 1, month 3, and month 6.
Time frame: Immediately after the TAME procedure
The technical success rate is judged according to the digital subtraction angiography (DSA). A successful procedure is determined by decreased neovascularization via targeted vessels embolization by the fused CT and angiography system.
Contact information is provided by the study sponsor or research team.
Tri-Service General Hospital (TSGH)
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06138314
Chronic Musculoskeletal Disease, Chronic Musculoskeletal Pain
Aveiro, Portugal
View Trial DetailsNCT05298566
Chronic Musculoskeletal Disease, Chronic Pain
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03882333
Chronic Musculoskeletal Disease, Chronic Pain
Falun, Dalarna County, Sweden
View Trial DetailsNCT04502992
Chronic Musculoskeletal Disease, Chronic Pain
Durham, New Hampshire, United States
View Trial Details